Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cyclo Therapeutics, Inc. is a biotech company developing cyclodextrin-based therapies for neurodegenerative diseases, primarily Niemann-Pick Type C. Its lead candidate, Trappsol Cyclo, aims to treat systemic and neurological symptoms, with ongoing clinical trials and regulatory efforts. The company also explores applications for Alzheimer’s disease and maintains a legacy business selling cyclodextrins for pharmaceutical and diagnostic uses.
This description was generated via AI from an annual report. Updated about 1 year ago.